News

Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds

Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary…

1 year ago

Updates from NurExone: Growth Conference Presentation and Website Relaunch

TORONTO and HAIFA, Israel, July 05, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the…

1 year ago

Bionano Announces up to $30 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

$10 million upfront with up to an additional $20 million upon the exercise in full of clinical milestone-linked Series WarrantsSAN…

1 year ago

Extendicare Announces Timing of 2024 Second Quarter Results and Conference Call

MARKHAM, Ontario, July 05, 2024 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced today that it…

1 year ago

Breast Tissue Expander Market size is set to grow by USD 282.4 million from 2024-2028, Increasing prevalence of breast cancer boost the market, Technavio

NEW YORK, July 4, 2024 /PRNewswire/ -- The global breast tissue expander market size is estimated to grow by USD 282.4 million…

1 year ago

Global Microscopy Market to Reach USD 10.6 Billion by 2029 driven by Healthcare Innovations | MarketsandMarkets™

CHICAGO, July 4, 2024 /PRNewswire/ -- The global microscopy market is poised for significant growth, expected to reach USD 10.6 billion…

1 year ago

FSD Pharma Files Amended and Restated Material Change Report

Toronto, Ontario--(Newsfile Corp. - July 4, 2024) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) ("FSD Pharma" or…

1 year ago

CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe

MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) -- Global biotechnology leader CSL Behring (ASX: CSL) today announced that two hemophilia…

1 year ago

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer

SKYSCRAPER-06 evaluating tiragolumab plus Tecentriq and chemotherapy did not meet the primary endpoints of progression-free survival at primary analysis and…

1 year ago

ICPO Foundation partners with Nuclear Medicine Research Infrastructure (NuMeRI) to establish an ICPO Collaborating Center

ICPO Center NuMeRI ICPO Foundation signed the contract with Nuclear Medicine Research Infrastructure (NuMeRI) to establish an ICPO Collaborating Center…

1 year ago